Development
NeuroOne Medical Technologies Corporation
NMTC
$0.76
-$0.04-5.00%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -37.72% | -63.12% | 1,868.44% | 1,173.77% | 3,814.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.72% | -63.12% | 1,868.44% | 1,173.77% | 3,814.71% |
| Cost of Revenue | 29.83% | 52.91% | 80.23% | 67.50% | 52.66% |
| Gross Profit | -909.12% | -424.14% | -33.77% | -34.89% | 88.70% |
| SG&A Expenses | 30.64% | -16.43% | 21.75% | 0.16% | -4.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.23% | 14.51% | 48.20% | 27.96% | 17.71% |
| Operating Income | -90.01% | -126.02% | -27.12% | -14.25% | 36.48% |
| Income Before Tax | -93.03% | -128.12% | -25.69% | -15.20% | 38.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -93.03% | -128.12% | -25.69% | -15.20% | 38.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.03% | -128.12% | -25.69% | -15.20% | 38.28% |
| EBIT | -90.01% | -126.02% | -27.12% | -14.25% | 36.48% |
| EBITDA | -90.55% | -126.97% | -26.50% | -13.88% | 37.20% |
| EPS Basic | -30.52% | -66.04% | -15.79% | -13.61% | 41.38% |
| Normalized Basic EPS | -30.58% | -71.13% | -15.77% | -10.58% | 41.49% |
| EPS Diluted | -30.52% | -66.04% | -15.79% | -13.61% | 41.38% |
| Normalized Diluted EPS | -30.58% | -71.13% | -15.77% | -10.58% | 41.49% |
| Average Basic Shares Outstanding | 47.84% | 37.33% | 8.56% | 1.39% | 5.34% |
| Average Diluted Shares Outstanding | 47.84% | 37.33% | 8.56% | 1.39% | 5.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |